Business Description
![Cocrystal Pharma Inc Cocrystal Pharma Inc logo](https://static.gurufocus.com/logos/0C000013Z1.png?14)
Cocrystal Pharma Inc
NAICS : 325412
SIC : 2834
ISIN : US19188J3005
Description
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 11.99 | |||||
Equity-to-Asset | 0.85 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | -0.09 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -2.1 | |||||
3-Year EPS without NRI Growth Rate | -1.7 | |||||
3-Year FCF Growth Rate | 11.2 | |||||
3-Year Book Growth Rate | -33.8 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 55.86 | |||||
9-Day RSI | 58.29 | |||||
14-Day RSI | 60.26 | |||||
6-1 Month Momentum % | 7.32 | |||||
12-1 Month Momentum % | -20 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 10.3 | |||||
Quick Ratio | 10.3 | |||||
Cash Ratio | 9.18 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -20.1 | |||||
Shareholder Yield % | -2.56 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -56.21 | |||||
ROA % | -50.9 | |||||
ROIC % | -999.6 | |||||
ROC (Joel Greenblatt) % | -1591.27 | |||||
ROCE % | -66.36 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.15 | |||||
Price-to-Tangible-Book | 1.15 | |||||
EV-to-EBIT | -0.29 | |||||
EV-to-EBITDA | -0.3 | |||||
EV-to-FCF | -0.37 | |||||
Price-to-Net-Current-Asset-Value | 1.26 | |||||
Price-to-Net-Cash | 1.46 | |||||
Earnings Yield (Greenblatt) % | -344.83 | |||||
FCF Yield % | -62.21 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cocrystal Pharma Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -1.524 | ||
Beta | 0.96 | ||
Volatility % | 65.62 | ||
14-Day RSI | 60.26 | ||
14-Day ATR (€) | 0.10396 | ||
20-Day SMA (€) | 2.167 | ||
12-1 Month Momentum % | -20 | ||
52-Week Range (€) | 1.24 - 2.82 | ||
Shares Outstanding (Mil) | 10.17 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Cocrystal Pharma Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Cocrystal Pharma Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Cocrystal Pharma Inc Frequently Asked Questions
What is Cocrystal Pharma Inc(STU:8CC)'s stock price today?
The current price of STU:8CC is €2.30. The 52 week high of STU:8CC is €2.82 and 52 week low is €1.24.
When is next earnings date of Cocrystal Pharma Inc(STU:8CC)?
The next earnings date of Cocrystal Pharma Inc(STU:8CC) is 2024-08-14 Est..
Does Cocrystal Pharma Inc(STU:8CC) pay dividends? If so, how much?
Cocrystal Pharma Inc(STU:8CC) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |